文献速递肾小球疾病肾移植

单克隆丙种球蛋白病相关C3肾小球病:慢性组织学病变的影响及克隆靶向治疗的益处

C3 glomerulopathy associated with monoclonal gammopathy: impact of chronic histologic lesions and beneficial effects of clone-targeted therapies.
PubMed 文献 · Nephrol Dial Transplant · 2022-01-01

本研究为回顾性多中心观察性研究,纳入1995至2021年诊断的23例C3G-MIg患者,分析临床病理特征及结局。中位随访40个月,39%患者达肾衰竭,慢性度评分高者预后差;克隆靶向治疗及血液学缓解与更好肾脏生存相关,肾移植受者结局差。

要点

  • C3G组织学指数可用于C3G-MIg患者预测肾脏预后,慢性度评分越高结局越差。
  • 克隆靶向治疗及达到血液学缓解与更好的肾脏预后相关。
  • 肾移植受者中C3G-MIg结局极差,71%达肾衰竭。

核心结论

  • C3G组织学指数可预测C3G-MIg肾脏预后,慢性度评分高与更差结局相关。
  • 克隆靶向治疗及血液学缓解与更好肾脏预后相关。

研究设计与样本

  • 回顾性、多中心、观察性研究,纳入1995至2021年诊断的C3G-MIg患者23例,中位年龄63岁(IQR 48-70),57%为男性。
  • 所有患者均行替代补体通路基因检测,使用C3G组织学指数分析疾病活动度和慢性度,采用描述性统计和倾向性评分匹配(PSM)评估主要结局(肾衰竭)。

主要发现

  • 中位随访40个月(IQR 14-69),9例(39%)达肾衰竭,其肾活检总慢性度评分显著更高。
  • 接受克隆靶向治疗者生存显著更高;达到血液学缓解者肾脏生存显著更高。
  • 肾移植受者结局极差,7例中5例(71%)达肾衰竭。
  • PSM调整年龄、肾功能、蛋白尿和慢性度评分后,伴/不伴MIg的C3G患者肾脏生存无显著差异。

关键数值与推荐

  • IgG kappa为最常见MIg(65%),7例(30%)在移植肾诊断C3G-MIg,5例(22%)有C3肾炎因子,5例(22%)有抗因子H抗体,1例携带CFH基因致病性变异。

临床怎么用

  • 对C3G-MIg患者应评估肾活检慢性度评分以预测肾脏预后。
  • 克隆靶向治疗及追求血液学缓解可能改善肾脏预后。
  • 肾移植受者合并C3G-MIg时需警惕极差结局。

局限性

  • 回顾性、观察性设计,样本量小(23例),可能存在选择偏倚和混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: C3 glomerulopathy associated with monoclonal gammopathy (C3G-MIg) is a rare entity. Herein we analysed the clinical and histologic features of a cohort of C3G-MIg patients. METHODS: We conducted a retrospective, multicentre, observational study. Patients diagnosed with C3G-MIg between 1995 and 2021 were enrolled. All had genetic studies of the alternative complement pathway. The degree of disease activity and chronicity were analysed using the C3G histologic index. Descriptive statistics and propensity score matching (PSM) analysis were used to evaluate the main outcome of the study [kidney failure (KF)]. RESULTS: The study group included 23 patients with a median age 63 of years [interquartile range (IQR) 48-70], and 57% were males. Immunoglobulin G kappa was the most frequent MIg (65%). The diagnosis of C3G-MIg was made in transplanted kidneys in seven patients (30%). Five (22%) patients had C3 nephritic factor and five (22%) had anti-factor H antibodies. One patient carried a pathogenic variant in the CFH gene. During a follow-up of 40 months (IQR 14-69), nine patients (39%) reached KF and these patients had a significantly higher total chronicity score on kidney biopsy. Patients who received clone-targeted therapy had a significantly higher survival compared with other management. Those who achieved haematological response had a significantly higher kidney survival. Outcome was remarkably poor in kidney transplant recipients, with five of them (71%) reaching KF. By PSM (adjusting for age, kidney function, proteinuria and chronicity score), no significant differences were observed in kidney survival between C3G patients with/without MIg. CONCLUSIONS: The C3G histologic index can be used in patients with C3G-MIg to predict kidney prognosis, with higher chronicity scores being associated with worse outcomes. Clone-targeted therapies and the development of a haematological response are associated with better kidney prognosis.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Caravaca-Fontán F, Lucientes L, Serra N, et al. C3 glomerulopathy associated with monoclonal gammopathy: impact of chronic histologic lesions and beneficial effects of clone-targeted therapies. Nephrol Dial Transplant. 2022. PMID: 34677610. doi:10.1093/ndt/gfab302

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。